Last Updated: 03/24/21
Current CIP Initiatives
This page lists current opportunities from CIP.
For information about the funding process, go to Mechanisms or
Guidelines.
The NCI’s Division of Extramural Activities provides information about newly approved concepts, which may become RFAs and PAs.
Check the Concepts Cleared at the NCI Board of Scientific
Advisors Meeting web site for the earliest possible information about future initiatives.
CIP Initiatives
| CIP Scientific Contact |
Link to Initiative |
| Yisong Wang, Ph.D. |
RFA-CA22-028 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial required) |
| Yisong Wang, Ph.D. |
RFA-CA22-029 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) |
| Yisong Wang, Ph.D. |
RFA-CA22-030 Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed) |
| Yisong Wang, Ph.D. |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) |
| Yisong Wang, Ph.D. |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) |
Robert J. Nordstrom, Ph.D.
Darrell Tata, Ph.D. |
NOT-CA-21-032: Notice of Special Interest (NOSI): Translation of Quantitative Imaging tools and Methods for the Academic Industrial Partnership |
| Yantian Zhang, Ph.D. |
PAR-22-090: Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed) |
| Yantian Zhang, Ph.D. |
PAR-22-091: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) |
| Chiayeng Wang, Ph.D |
PAR-21-294: Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) |
| Chiayeng Wang, Ph.D |
PAR-21-290: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) |
| Yisong Wang, Ph.D. |
NOT-DE-21-010: Precision Imaging of Oral Lesions |
| Darrel Tata, Ph.D. |
PAR-20-155: Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) |
Christopher Hartshorn, Ph.D.
Piotr Grodzinski, Ph.D. |
PAR-20-284: Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed) |
| Lalitha Shankar, M.D., PhD. |
NOT-CA-21-028: Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers |
| Piotr Grodzinski, Ph.D. |
PAR-20-116: Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) |
| Lalitha Shankar, M.D., Ph.D. |
PA-19-112: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional) |
| Lalitha Shankar, M.D., Ph.D. |
PA-19-111: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional) |
| Lalitha Shankar, M.D., Ph.D. |
PAR-21-033: National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) |
| Darrel Tata, Ph.D. |
PAR-21-166: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Not Allowed) |
| Darrel Tata, Ph.D. |
PAR-21-206: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Optional) |
Other NCI & NIH Imaging-Relevant Initiatives
| Scientific Contact |
Link to Initiative |
Piotr Grodzinski, Ph.D.
Chiayeng Wang, Ph.D |
PAR-22-126 (R21): Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) |
Piotr Grodzinski, Ph.D.
Chiayeng Wang, Ph.D |
PAR-22-127 (R01): Focused Technology Research and Development (R01 Clinical Trial Not Allowed) |
| Yisong Wang, Ph.D. |
RFA-CA22-028 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required) |
| Yisong Wang, Ph.D. |
RFA-CA22-029 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) |
| Yisong Wang, Ph.D. |
RFA-CA22-030 Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed) |
| Pushpa Tandon |
PAR-23-055 (R01): Co-infection and Cancer (R01 Clinical Trial Not Allowed) |
| Pushpa Tandon |
PAR-23-056 (R21): Co-infection and Cancer (R21 Clinical Trial Not Allowed) |
| Juli Klemm, Ph.D. |
RFA-CA-22-021 (R21): Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) |
| Juli Klemm, Ph.D. |
RFA-CA-22-022 (U01): Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) |
| Juli Klemm, Ph.D. |
RFA-CA-22-023 (U24 Advanced Development): Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) |
| Juli Klemm, Ph.D. |
RFA-CA-22-024 (U24 Sustainment): Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) |
| Chiayeng Wang, Ph.D. |
NOT-EB-20-017 Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications |
| Chiayeng Wang, Ph.D. |
PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) |
| Chiayeng Wang, Ph.D. |
PAR-20-276: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) |
| Lalitha Shankar, M.D., Ph.D. |
PAR21-329 Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) |
